Why the Nanosonics (ASX:NAN) share price fell 8% in May

The Nanosonics share price struggled in May. We take a closer look at what happened.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Nanosonics Ltd (ASX: NAN) share price struggled in May.

During the month, the healthcare technology company's shares shaved off 8%.

A shocked and stressed man looking at his laptop and trying to absorb bad news about the Netwealth share price falling

Image source: Getty Images

What happened to the Nanosonics share price in May?

Unfortunately for Nanosonics' shareholders, weakness in the healthcare sector broadly doesn't appear to be the fault. In fact, the S&P/ASX 200 Health Care Index (ASX: XHJ) outpaced the broader market, delivering a return of 3.5% in May. Meanwhile, the S&P/ASX 200 Index (ASX: XJO) climbed 1.9%.

The disappointing month for Nanosonics might be due to the absence of catalysts. During May, the only announcements from the company pertained to a change in director's interests. CEO, Michael Kavanagh exercised his performance rights to acquire 342,735 shares in Nanosonics.

Without any new information, investors could still be focusing on the decrease in first half revenue. Total revenue for H1 FY21 fell 11% year-over-year following a reduction in purchases by GE Healthcare due to COVID-19.

Looking forward

While the first half looked to be challenging for the company, it instilled confidence for the second half. Further vaccination rollouts and improved access to hospitals formed the basis of the optimistic outlook.

Referring to Nanosonics' second half expectations, Mr Kavanagh said:

Based on current market improvements the company is anticipating ongoing growth in total revenue and profitability into the second half, driven by increasing installed base growth and increased usage of consumables across all regions.

However, this statement was made back in February. Since then, Australia has suffered vaccination rollout issues and additional lockdowns. This has potentially made investors uneasy regarding a second-half rebound.

Healthcare shares that had a better month

May was a good month for the large-cap ASX-listed healthcare shares. For example, CSL Limited (ASX: CSL) added 7% as data indicated a rise in foot traffic at plasma collection centres. Furthermore, Hearing device maker Cochlear Ltd (ASX: COH) rose 2% during May, with Macquarie analysts giving it a $245 price target.

Will June be a better month for the Nanosonics share price, or will the large-cap trend continue? Shareholders will be watching eagerly.

Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. and CSL Ltd. The Motley Fool Australia owns shares of and has recommended Nanosonics Limited. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Share Market News

Testing again

Read more »

Share Market News

Aaron Test 2

Read more »

Share Market News

Aaron Test

Read more »

Share Market News

JP Test

Read more »

Share Market News

JP Test

Read more »

Portrait of Discovery Fund portfolio managers Mark Devcich and Chris Bainbridge
Share Market News

Test

Portfolio managers Mark Devcich (left) and Chris Bainbridge. Image source: Discovery Fund test test

Read more »

a man in a hoodie grins slyly as he sits with his hands poised on a keyboard. He is superimposed with a graphic image of a computer screen asking for a password, suggesting he is a hacker.
Share Market News

Another ASX 200 company has been hit with a cyber incident. Here's what we know

Hackers have breached the systems of this ASX 200 company.

Read more »

a woman
Broker Notes

5 ASX 200 shares that inflation can't touch: expert

Regardless of whether you're a bull or a bear, cost pressures are a factor when buying stocks at the moment.

Read more »